Securities code: Shanghai General Healthy Information And Technology Co.Ltd(605186) securities abbreviation: Shanghai General Healthy Information And Technology Co.Ltd(605186) Announcement No.: 2022009 Shanghai General Healthy Information And Technology Co.Ltd(605186)
Announcement on the reduction of shares held by more than 5% of shareholders through centralized bidding for more than half of the time and the progress of reduction
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important content tips:
Basic information of shareholders’ shareholding
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as ” Hybio Pharmaceutical Co.Ltd(300199) “) held 13853627 shares of the company before the initial restricted shares of Shanghai General Healthy Information And Technology Co.Ltd(605186) (hereinafter referred to as “the company”) were listed, accounting for 10.19% of the current total share capital of the company. The restricted period of the aforesaid shares expired on December 21, 2021, and the restricted listing and circulation was lifted on December 22, 2021.
From the date of the company’s initial listing of restricted shares to the implementation of the centralized bidding reduction plan, Hybio Pharmaceutical Co.Ltd(300199) reduced 680000 shares of the company through block trading, with the reduction proportion reaching 0.50% of the company’s current total share capital. After the reduction, 13173627 shares were held, accounting for 9.69% of the company’s current total share capital.
As of the disclosure date of this announcement, Hybio Pharmaceutical Co.Ltd(300199) holds 12124527 shares of the company, accounting for 8.92% of the current total share capital of the company.
Progress of centralized bidding reduction plan
On December 24, 2021, the company disclosed the announcement on the share reduction plan of more than 5% shareholders (Announcement No.: 2021043), Hybio Pharmaceutical Co.Ltd(300199) due to its own business needs, it plans to reduce the shares of the company through centralized bidding, the number of shares reduced shall not exceed 272000, the proportion of shares reduced shall not exceed 2% of the total share capital of the company, and the total number of shares reduced in any continuous 90 natural days shall not exceed 1% of the total share capital of the company, The reduction price will be determined according to the market price.
From the date of the company’s initial listing of restricted shares to January 24, 2022, Hybio Pharmaceutical Co.Ltd(300199) through centralized bidding and block trading, the cumulative reduction of the company’s shares reached 1.05%. For details, see the company’s report in 2022
Suggestive announcement on the reduction of more than 5% shareholders to 1% disclosed on January 26 (Announcement No.:
2022005)
On April 15, 2022, the company received the notification letter on the progress of share reduction sent by Hybio Pharmaceutical Co.Ltd(300199) and received it
Yu pharmaceutical’s share reduction plan has been implemented for more than half of the time, and the share reduction plan has not been implemented yet.
1、 Basic information of the subject of centralized bidding reduction before reduction
Number of shares held
Shareholder name shareholder identity shareholding proportion current shareholding source
(shares)
Shenzhen Hybio Pharmaceutical Co.Ltd(300199) Co., Ltd
More than 5% non largest shareholder 9.69% acquired before IPO: 13173627 shares Co., Ltd
The above reduction subjects have no concerted action.
2、 Implementation progress of centralized bidding reduction plan
(I) shareholders disclose the implementation progress of the centralized bidding reduction plan for the following reasons:
The reduction time is more than half
Reduction price current shareholding current reduction quantity reduction ratio total reduction amount of the reducing party
Shareholder name reduction period interval (yuan) number of shares (shares) example amount (yuan)
/Share (share) ratio
Shenzhen Hanyu 2022 / 1 / 17
Concentrated competition 37.47-
Pharmaceutical shares 1491000.11% ~ 5586777121245278.92% transaction price 37.47
Ltd. April 17, 2022
Note: Hybio Pharmaceutical Co.Ltd(300199) from the date of listing of the company’s initial restricted shares to the date of disclosure of this announcement, the cumulative decrease through block trading
Holding 1580000 shares of the company, accounting for 1.16% of the current total share capital of the company. Among them, in this centralized bidding reduction plan
Before the implementation, 680000 shares of the company were reduced through block trading, with a reduction ratio of 0.50%; In this centralized bidding
During the implementation of the shareholding plan, 900000 shares of the company were reduced through block trading, with a reduction ratio of 0.66%.
(II) whether the reduction is consistent with the plans and commitments previously disclosed by the shareholders √ yes □ no (III) whether the listed company discloses major matters such as high transfer or planning merger and reorganization within the reduction time interval □ yes √ no (IV) the impact of the reduction on the company
The implementation of this share reduction plan will not lead to the change of the company’s control and will not have a significant impact on the company’s governance structure and sustainable operation. (V) other matters required by the exchange
III. risk tips related to the centralized bidding reduction plan (I) uncertainty risk of the implementation of the reduction plan, such as the preconditions and restrictive conditions for the implementation of the plan, as well as the specific conditions for the achievement or elimination of relevant conditions, etc
The reduction plan has not been implemented yet. Hybio Pharmaceutical Co.Ltd(300199) will choose whether and how to implement the reduction plan according to its own capital arrangement, stock market price and other factors. There are uncertainties in the reduction quantity and price. (II) whether the implementation of the share reduction plan will lead to the risk of change in the control of the listed company □ yes √ no (III) other risks
As of the disclosure date of this announcement, Hybio Pharmaceutical Co.Ltd(300199) this share reduction plan has not been implemented yet. The company will continue to pay attention to the progress of the implementation of the share reduction plan, and fulfill the obligation of information disclosure in time in accordance with the provisions of relevant laws, regulations and normative documents. Please pay attention to the investment risks.
It is hereby announced.
Shanghai General Healthy Information And Technology Co.Ltd(605186) board of directors April 18, 2022
